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The expression of multidrug resistance-associated protein (MRP1) results in ATP-dependent reduction of drugs’ concentration in cancer cells,
i.e., multidrug resistance (MDR). Since the majority of projects are concentrated on the search of the new MDR modulators, there are very few
reports on drug-induced stimulation of MDR transporters activity. In the present work, by means of functional fluorescence assay we have shown
that MRP1-mediated efflux of 2V,7V-bis-(3-carboxypropyl)-5-(and-6)-carboxyfluorescein (BCPCF) out of human erythrocytes is stimulated by
phenothiazine maleates that have been already identified as P-glycoprotein inhibitors. Phenothiazine maleates-induced stimulation of ATP-
dependent uptake of 2V,7V-bis-(3-carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF) into inside-out membrane vesicles prepared from
erythrocyte membranes has been also demonstrated. Moreover, it was shown that phenothiazine maleates exerted stimulating effect on ATPase
activity measured in erythrocyte membranes. To our best knowledge, this report is the first one demonstrating that compounds able to inhibit
transport activity of P-glycoprotein can stimulate MRP1 transporter. We conclude that phenothiazine maleates probably exert their stimulatory
effect on MRP1 by direct interaction with the protein at the site different from the substrate binding site.
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Erythrocyte1. Introduction
Overexpression of multidrug resistance-associated protein
(MRP1; ABCC1) confers multidrug resistance (MDR) on
tumour cells, the phenomenon characterized by ATP-dependent
reduction of anticancer drug concentration inside the cells that
leads to frequent chemotherapy failures. MRP1 is a 190-kDa
protein that belongs to ATP-binding cassette (ABC) superfam-
ily [1]. Composed of two hydrophobic transmembrane0005-2736/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamem.2005.11.011
Abbreviations: MRP1 (ABCC1), multidrug resistance-associated protein 1;
MDR, multidrug resistance; BCECF, 2V,7V-bis-(3-carboxyethyl)-5-(and-6)-
carboxyfluorescein; P-gp, P-glycoprotein; BCPCF, 2V,7V-bis-(3-carboxypro-
pyl)-5-(and-6)-carboxyfluorescein; PhMs, phenothiazine maleates; PBS, phos-
phate-buffered saline; GSH, glutathione
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domain (NBD), MRP1 shares core structure with many other
ABC superfamily members (e.g., P-glycoprotein). The charac-
teristic feature of MRP1 is the presence of additional NH2-
proximal transmembrane domain. Glutathione, glucuronate and
sulfate conjugates of many endogenous and xenobiotic sub-
stances were shown to be MRP1 substrates [2]. MRP1 is
expressed not only in tumours but it is also physiologically
present in many cell types, e.g., hepatocytes, erythrocytes, mast
cells, eosinophils and cardiac cells [1]. In human erythrocytes,
apart from MRP1, two other ABC-transporters were identified,
namely MRP4 and MRP5 [3], whereas no P-glycoprotein
expression was found in this cell type [4].
Since the pioneer work of Homolya et al. [5], who have
demonstrated that fluorescent dyes can be the substrates of P-
glycoprotein, functional tests are widely used to study MDR
transporters activity. Besides acetoxymethyl ester of calceinta 1720 (2005) 52 – 58
http://www
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bis-(3-carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF)
was found to be MRP1 substrate [4,8]. The method used in
the present work and in previous studies [4,9] takes an
advantage of the fact that the non-fluorescent acetoxymethyl
ester of BCECF (or its structural analogue BCPCF) rapidly
penetrates into erythrocytes where cellular esterases cleave the
ester bond thus releasing highly fluorescent, free acid form of
BCECF (or BCPCF) which in turn is actively pumped out of
the cell. Rychlik et al. [4] have shown that BCECF efflux out of
erythrocytes was inhibited by indomethacin, probenecid and
benzbromarone, typical set of organic anion transport inhibi-
tors. The authors have also demonstrated that QCRL3, specific
anti-MRP1 monoclonal antibody, inhibited BCECF uptake into
inside-out membrane vesicles prepared from red blood cells.
Virtually the same inhibition profile was observed by
Klokouzas et al. [10] in their study of dinitrophenyl S-
glutathione transport in human erythrocytes. Both groups
concluded that MRP1 was responsible for transport activity
observed by them in red blood cells. However, the participation
of MRP5 in BCECF efflux from human erythrocytes cannot be
excluded as this protein was also reported to transport BCECF
[11].
Phenothiazine maleates (PhMs) are newly synthesized
compounds that have been shown previously to inhibit P-
glycoprotein in multidrug resistant cancer cells [12,13], to
possess antibacterial and antifungal activity [14] and to
modulate biophysical properties of model membranes [13].
In the present study, we demonstrate the stimulation of 2V,7V-
bis-(3-carboxypropyl)-5-(and-6)-carboxyfluorescein (BCPCF)
efflux out of human erythrocytes by phenothiazine maleates.
Also the enhanced ATP-dependent uptake of 2V,7V-bis-(3-
carboxyethyl)-5-(and-6)-carboxyfluorescein (BCECF) into in-
side-out vesicles prepared from red blood cell membrane is
shown in the presence of PhMs. The stimulation of Mg2+-
dependent ATPase activity measured in erythrocyte membrane
by phenothiazine derivatives has also been observed. To our
best knowledge, this report is the first to show that P-
glycoprotein inhibitors can stimulate transport activity of
MRP1. The systematic studies of this phenomenon are
performed. We conclude that phenothiazine derivatives prob-
ably interact with MRP1 at the site different from the substrate
binding site. Our data support the presumption that MRP1
possess at least two binding sites at which substrates or
modulators can interact with protein.Fig. 1. Chemical structure of phenothiazine maleates. The ring substituent is:
H- in 3HPhM and 4HPhM; Cl- in 3ClPhM and 4ClPhM; CF3- in 3FPhM and
4FPhM. The length of the alkyl bridge connecting the phenothiazine nucleus
with side chain amino group is 3 carbon atoms in 3HPhM, 3ClPhM, 3FPhM;
and 4 carbon atoms in 4HPhM, 4ClPhM, 4FPhM.2. Materials and methods
2.1. Materials
2V,7V-bis-(3-carboxypropyl)-5-(and-6)-carboxyfluorescein acetoxymethyl
ester (BCPCF-AM) and 2V,7V-bis-(3-carboxyethyl)-5-(and-6)-carboxyfluores-
cein (BCECF) were purchased from Molecular Probes (Eugene, OR). Sodium
orthovanadate, benzbromarone, ouabain, phenylmethylsulphonylfluoride
(PMSF), AMP, ATP, phosphocreatine, and creatine phosphokinase were from
Sigma (St. Louis, MO). Sodium dodecyl sulfate (SDS) was from Amresco
(Solon, OH) and Triton X-100 was purchased from Merck (Whitehouse Station,
NJ). All other reagents used were of analytical grade.Phenothiazine maleates (PhMs) were synthesized as described previously
[14]. The chemical structure of PhMs is shown in Fig. 1. Six PhMs studied
differ in the type of substituent at position 2 (H-, Cl- or CF3-) and in the length
of the alkyl bridge connecting the phenothiazine nucleus with side chain amino
group (3 or 4 carbon atoms). Stock solutions of BCPCF-AM, BCECF, PhMs
and benzbromarone were prepared in DMSO. Orthovanadate, Triton X-100 and
SDS were dissolved in water.
2.2. Erythrocyte preparation
Human blood was obtained from healthy volunteers by vein puncture. The
blood was washed (2000g, 5 min, 4 -C) with isoosmotic PBS solution. The
precipitate was resuspended in PBS and passed through the a-cellulose column
to remove leukocytes and platelets [15]. Subsequently, the erythrocytes were
washed three more times and resuspended in the transport buffer containing 6.1
mM Na2HPO4, 1.4 mM NaH2PO4, 138 mM NaCl, 5 mM KCl, 1 mM MgCl2,
5.6 mM glucose (pH 7.4). Cells were stored at 4 -C and used within 36 h.
2.3. BCPCF transport studies
Measurement of BCPCF efflux out of the cells was performed using the
functional test developed by Rychlik et al. [4]. Shortly, the erythrocytes
suspended in transport buffer (at 5% hematocrit) were incubated with an
appropriate concentration of PhMs and/or inhibitor (15 min, room temperature,
darkness). The samples were then mixed with an equal volume of ice-cold 2
AM BCPCF-AM solution in the same buffer and cells were allowed to load for
10 min on ice. The cells were incubated at 37 -C for 0, 20, 40 and 60 min in
darkness. The incubation was stopped by putting the samples on ice and
subsequent centrifugation (14,000g, 3 min, 4 -C). MRP1 transport activity
was monitored by measuring BCPCF fluorescence in supernatant (excitation
and emission wavelengths were 475 nm and 525 nm, respectively). Percentage
of MRP1 stimulation/inhibition was determined by comparing the slopes of
fluorescence intensity versus time dependencies for control sample and the
samples containing PhMs and/or inhibitor. It was checked that PhMs
themselves did not influence BCPCF fluorescence. DMSO concentration in
the samples never exceeded 0.5%. Care was also taken to maintain hemolysis
level in the samples below 1%. Experiments were performed in triplicate, for
each repetition blood from different donor was used.
2.4. Membrane preparation
Erythrocytes were prepared as described above. PBS was replaced by
isoosmotic Tris buffer (20 mM Tris–HCl, 155 mM NaCl, pH 7.0) when
membranes were used for ATPase activity measurements. Erythrocyte ghosts
and inside-out vesicles were prepared according to modified procedure of Steck
and Kant [16]. Erythrocytes harvested after passage through a-cellulose
column were lysed in 50 volumes of ice-cold buffer containing 20 mM Tris–
HCl, 1 mM EDTANa2, 0.575 mM phenylmethylsulphonylfluoride (pH 7.4 at 4
-C). The lysate was centrifuged (23,000g, 12 min, 4 -C) and supernatant
removed. This step was repeated twice. The pellet after last wash was
Table 1
Stimulation of BCPCF efflux out of erythrocytes by phenothiazine maleates
(meanTS.D. of three independent experiments) measured in buffer containing
6.1 mM Na2HPO4, 1.4 mM NaH2PO4, 138 mM NaCl, 5 mM KCl, 1 mM
MgCl2, 5.6 mM glucose (pH 7.4) at 5% hematocrit
Compound Stimulation at
20 AM
[% of control]
Maximal
stimulation
[% of control] Concentration [AM
3HPhM 130.1T20.3 152.6T16.0 100
4HPhM 154.9T4.5 171.1T15.1 50
3ClPhM 126.4T18.9 171.6T18.4 50
4ClPhM 153.1T11.9 155.0T2.7 15
3FPhM 107.9T10.5 114.3T3.2 15
4FPhM 143.0T2.2 143.0T2.2 20
Fluorescent probe concentration: 2 AM. Percentage of stimulation was
determined by comparing the slopes of fluorescence intensity versus time
dependencies for control sample and the samples containing PhMs.
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mM Tris–HCl, 1 mM EDTANa2, 250 mM sucrose (pH 8.1 at 4 -C) and
incubated overnight on ice. After the incubation the suspension was centrifuged
(29,000g, 30 min, 4 -C) and the vesicle pellet was resuspended in VB by
vigorous syringing with a 21-gauge needle. The protein concentration in the
membrane preparations was determined according to Lowry et al. [17]. The
percentage of inside-out vesicles in preparation was assessed by the comparison
of accessible and total activity of acetylcholinesterase using method of Ellman
et al. [18]. On average 88T2% of vesicles were inside-out. Erythrocyte ghosts
and inside-out vesicles were snap-frozen and stored at 80 -C until use.
2.5. Uptake studies in inside-out vesicles
The ATP-dependent accumulation of BCECF inside membrane vesicles
was measured in buffer containing 10 mM Tris–HCl, 250 mM sucrose, 10 mM
MgCl2, 0.66 mM ouabain, 10 mM phosphocreatine, 1 U/ml creatine
phosphokinase (pH 7.4 at 37 -C) with addition of 2.5 mM ATP or 2.5 mM
AMP in control samples. Inside-out vesicles (protein concentration 0.5 mg/ml)
were incubated with an appropriate concentration of PhMs (15 min, room
temperature, darkness). The samples were then mixed with an equal volume of
ice-cold BCECF solution (final concentration of BCECF was 12.5 AM) and
ATP or AMP was added. The cells were incubated at 37 -C for 60 min in
darkness. The reaction was stopped by the addition of 1.2 ml of ice-cold VB
and subsequent centrifugation (18,000g, 5 min, 4 -C). The supernatant was
removed and the vesicle pellet was washed twice with 1 ml of VB. After last
wash, the pellet was dissolved in 1 ml of 1% (v/v) Triton X-100 in 10 mM Tris
(pH 10.0). After 20 min (room temperature, darkness) the fluorescence of
BCECF was measured (excitation and emission wavelengths were 475 nm and
525 nm, respectively). BCECF vesicle uptake was determined as a difference of
the fluorescence value measured in the presence of ATP and AMP. It was
checked that PhMs themselves did not influence BCECF fluorescence. DMSO
concentration in the samples never exceeded 1%. Experiments were performed
in triplicate.
2.6. ATPase activity determination
Erythrocyte ghosts (protein concentration 0.36 mg/ml) were incubated with
an appropriate concentration of PhMs (15 min, room temperature, darkness) in
buffer containing 100 mM Tris–HCl, 10 mM MgCl2, 0.1 mM ouabain (pH 7.4
at 37 -C). Then ATP was added (final concentration 1 mM) and the samples
were incubated at 37 -C (30 min, darkness) or on ice (control samples). The
reaction was stopped by the addition of an equal volume of 0.6 M
trichloroacetic acid and subsequent centrifugation (18,000g, 5 min, 4 -C).
The amount of inorganic phosphate in the supernatant was determined as the
complex of phosphomolybdate and malachite green by method of Van
Veldhoven and Mannaerts [19]. ATPase activity was determined as a difference
of absorbance value (at 610 nm) measured in the samples incubated at 37 -C
and on ice. DMSO concentration in the samples never exceeded 1%.
Experiments were performed in triplicate.
3. Results
The efflux of BCPCF out of erythrocytes remained linear for
at least 60 min under the conditions of functional test used in
the present study (data not shown) that is in agreement with
previous observations made by Rychlik et al. [4] in the same
experimental system. The outward BCPCF transport in our test
was inhibited by such nonspecific inhibitors of organic anion
transport as indomethacin, probenecid, fluoride ions and
benzbromarone, by ATPase inhibitor orthovanadate and by
MK-571 regarded as a specific MRP1 inhibitor (data not
shown). The IC50 values for all the inhibitors were similar to
the values obtained by other authors in BCPCF-erythrocyte
system [4,20,21]. Metabolic depletion also caused almostcomplete inhibition of BCPCF efflux (data not shown).
Following the reasoning of Rychlik et al. [4] (see Introduction),
we accepted the BCPCF transport test in erythrocyte system to
be indicative of MRP1 transport activity.
All six phenothiazine maleates studied stimulated MRP1
transport activity (Table 1). The maximal stimulation varied
between 15% and 70% being the highest in case of 4HPhM and
3ClPhM. Typically, phenothiazine maleates caused concentra-
tion-dependent increase of BCPCF efflux out of erythrocytes
(see example in Fig. 2). However, above certain concentration
of PhMs, their stimulatory activity stopped increasing and even
a small decrease was observed. Such an effect was observed for
all compounds studied. As PhMs caused erythrocyte hemolysis
start at different concentrations, the concentration range studied
was different for each compound. To compare MRP1
stimulating effect of phenothiazine maleates the concentration
of 20 AM was chosen as it was the highest concentration that
could be studied for all PhMs. At this concentration the
strongest stimulation was observed for 4HPhM and 4ClPhM.
Other compounds were weaker MRP1 stimulants and activity
of 3FPhM at this concentration was negligible. At 20 AM
phenothiazine maleates possessing 4 carbon atom alkyl bridge
connecting the phenothiazine nucleus with side chain amino
group were more effective MRP1 stimulating agents than
compounds with 3 carbon atom alkyl bridge.
The increased BCPCF efflux out of erythrocytes in the
presence of phenothiazine maleates is likely to be the result of
increased MRP1 transport activity. As phenothiazines in high
concentrations are supposed to exert detergent-like activity on
cell membranes we decided to check if the presence of free
BCPCF outside the erythrocytes could result from the reason
other than MRP1 stimulation, e.g., increased membrane
permeability. To investigate this problem we have examined
the influence of MRP1 inhibitors on BCPCF efflux in the
presence of 4HPhM, the most active compound studied. In the
presence of 25 AM of orthovanadate 4HPhM was not able to
stimulate outward BCPCF transport (Fig. 2). Similar effect was
observed when 50 AM of benzbromarone was used (data not
shown). The influence of 50 AM of 4HPhM on MRP1
inhibition by orthovanadate (Fig. 3A) and benzbromarone]
Fig. 2. The influence of phenothiazine derivative 4HPhM (black symbols) and
4HPhM plus 25 AM of orthovanadate (open symbols) on BCPCF efflux out of
human erythrocytes. Buffer: 6.1 mM Na2HPO4, 1.4 mM NaH2PO4, 138 mM
NaCl, 5 mM KCl, 1 mM MgCl2, 5.6 mM glucose (pH 7.4). Hematocrit: 5%.
Fluorescent probe concentration: 2 AM. Percentage of stimulation/inhibition
was determined by comparing the slopes of fluorescence intensity versus time
dependencies for control sample and the samples containing 4HPhM or
4HPhM/inhibitor.
Table 2
Stimulation of BCECF uptake into inside-out vesicles prepared from
erythrocyte membrane by phenothiazine maleates (meanTS.D. of three
independent experiments) measured in buffer containing 10 mM Tris–HCl,
250 mM sucrose, 10 mMMgCl2, 0.66 mM ouabain, 10 mM phosphocreatine, 1
U/ml creatine phosphokinase (pH 7.4 at 37 -C)
Compound Stimulation at 20 AM
[% of control]
3HPhM 115.5T11.0
4HPhM 157.3T7.8
3ClPhM 126.1T5.2
4ClPhM 139.1T14.0
3FPhM 120.7T10.9
4FPhM 133.8T2.4
Incubation: 60 min at 37 -C. Fluorescent probe concentration: 12.5 AM.
Protein concentration: 0.5 mg/ml. BCECF uptake into vesicles was
determined as a difference of the fluorescence intensity value (excitation at
475 nm, and emission at 525 nm) measured in the presence of ATP (2.5 mM)
and AMP (2.5 mM).
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increased BCPCF efflux by 70% in the absence of inhibitors. In
the presence of orthovanadate the stimulatory effect of 4HPhM
was not observed but the inhibitory activity of orthovanadate inFig. 3. Inhibition of BCPCF efflux out of human erythrocytes by orthovanadate
(A) and benzbromarone (B). Pure inhibitors were used (open symbols) and
inhibitors plus 50 AM of 4HPhM (black symbols). Experimental conditions as
in Fig. 2.the presence of 4HPhM was lower as compared to pure
inhibitor. Similar results were obtained for benzbromarone,
however in this case the stimulation of BCPCF efflux could be
observed at the lowest concentration of inhibitor used (1 AM).
This stimulation (c.a. 50%) was, however, smaller than the
effect of 4HPhM alone. Increasing benzbromarone concentra-
tion abolished MRP1 stimulation by the studied compound. At
benzbromarone concentration of 50 AM the BCPCF efflux
inhibition was the same in the sample containing pure inhibitor
and in the one with the addition of 4HPhM.
Additionally, the influence of nonionic detergent Triton X-
100 and anionic detergent SDS on BCPCF efflux out of
erythrocytes was investigated. SDS was found to inhibit
MRP1 transport activity (IC50 < 18 AM). On the other hand,
Triton X-100 was found to stimulate outward BCPCF efflux
by 50% at the concentration of 0.0009% (v/v) and by 65% at
0.0018% (v/v).Fig. 4. The influence of phenothiazine derivative 4HPhM on BCECF uptake
into inside-out vesicles prepared from erythrocyte membrane. Buffer: 10 mM
Tris–HCl, 250 mM sucrose, 10 mM MgCl2, 0.66 mM ouabain, 10 mM
phosphocreatine, 1 U/ml creatine phosphokinase (pH 7.4 at 37 -C).
Incubation: 60 min at 37 -C. Fluorescent probe concentration: 12.5 AM.
Protein concentration: 0.5 mg/ml. BCECF uptake into vesicles was
determined as a difference of the fluorescence intensity value (excitation at
475 nm, and emission at 525 nm) measured in the presence of ATP (2.5 mM)
and AMP (2.5 mM).
Table 3
Stimulation of ATPase activity in erythrocyte membrane by phenothiazine
maleates (meanTS.D. of three independent experiments) measured in buffer
containing 100 mM Tris–HCl, 10 mM MgCl2, 0.1 mM ouabain, 1 mM ATP
(pH 7.4 at 37 -C)
Compound Stimulation at
20 AM
[% of control]
Maximal
stimulation
[% of control] Concentration
[AM]
3HPhM 112.6T10.9 116.0T2.3 50
4HPhM 145.7T8.7 145.7T8.7 20
3ClPhM 124.0T15.6 124.0T15.6 20
4ClPhM 105.2T3.2 110.2T5.6 5
3FPhM 173.3T18.0 187.6T30.0 50
4FPhM 125.8T14.3 125.8T14.3 20
Protein concentration: 0.36 mg/ml. ATPase activity was determined as a
difference of inorganic phosphate amount released by samples incubated at 37
-C and on ice (incubation: 30 min).
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out vesicles prepared from erythrocyte membrane. ATP-
dependent uptake of BCECF into the vesicles was linear for
at least 60 min under the conditions of the experiment (data
not shown). All phenothiazine maleates studied were able to
stimulate BCECF transport into the vesicles (Table 2). The
percentage of stimulation of fluorescent probe transport by a
given PhM was similar in whole erythrocytes and in inside-
out vesicles. Similarly as in erythrocytes, the compounds
4HPhM and 4ClPhM (tested at 20 AM concentration) induced
the strongest MRP1 stimulation. Also in inside-out vesicles
phenothiazine maleates possessing 4 carbon atom alkyl bridge
connecting the ring system with side chain amino group were
found to be more effective MRP1 stimulating agents than
compounds with 3 carbon atom alkyl bridge. The dependence
of BCECF uptake into the vesicles and BCPCF efflux out of
erythrocytes on PhMs concentration were also similar
(compare Figs. 2 and 4).
Mg2+-dependent ATPase activity was also measured in
human erythrocyte membrane. In our experimental system, this
activity was inhibited by orthovanadate and fluoride ions and
stimulated by indomethacin, probenecid, benzbromarone and
MK-571 (data not shown). All phenothiazine maleates studied
stimulated ATPase activity when tested at the concentration of
20 AM (Table 3). The maximal stimulation varied between 10%
and 80% being the highest in case of 3FPhM and 4HPhM. No
correlation between the ability of a given phenothiazine
derivative to stimulate MRP1 transport activity and ATPase
activity in erythrocytes was observed.
4. Discussion
In the present study, we have demonstrated that phenothi-
azine maleates stimulate MRP1 transport activity in human
erythrocytes. PhMs increased both efflux of fluorescent probe
BCPCF out of intact erythrocytes and ATP-dependent uptake
of BCECF into inside-out vesicles prepared from erythrocyte
membrane. The similarity of the results obtained in the two
experimental procedures indicated that in both systems the
same transport activity was measured, i.e., MRP1-mediatedtransport of 2V,7V-bis-(3-carboxypropyl)- or 2V,7V-bis-(3-carbox-
yethyl)-5-(and-6)-carboxyfluorescein.
PhMs have been previously recognised as P-glycoprotein
inhibitors in cancer cells [12,13]. Neither P-gp inhibition
studied previously [13] nor MRP1 stimulation efficiency of
PhMs seemed to be correlated with compounds’ lipophilicity as
determined in [13].
The increased BCPCF efflux out of erythrocytes observed in
our experiments could not be caused by the changes in MRP1
transporter gene expression. Such an effect was excluded
because of the short time of the functional test used (60 min)
and by the use of mature erythrocytes as a model system as
these cells lack nuclei. The other possible reason of elevated
free BCPCF concentration outside the erythrocytes could be
the putative detergent-like activity of PhMs. It could be
suspected that these compounds in concentrations below
hemolysis start could produce some local defects in cell
membranes thereby increasing membrane permeability for
small molecules like BCPCF. We have, however, demonstrated
that the use of known MRP1 inhibitors such as benzbromarone
and orthovanadate was able to abolish the stimulating effect of
phenothiazine maleates. We therefore concluded that the
observed BCPCF efflux was caused by the stimulation of an
active transport system rather than by increasing membrane
permeability for BCPCF.
The influence of phenothiazine maleates on Mg2+-depen-
dent ATPase activity in human erythrocyte membrane was also
studied. All the compounds studied caused ATPase activity
stimulation. The lack of correlation between the degree of
MRP1 transport activity stimulation and ATPase activity
stimulation may the result of the complexity of model system
that is constituted by erythrocyte membrane. Rychlik et al. [4]
have demonstrated previously that MRP1 was the transporter
responsible for BCPCF and BCECF translocation across the
red blood cell membrane. However, in case of drug-stimulated
ATPase activity in erythrocyte membrane probably the activity
of more ATP-dependent transporters, such as MRP4 and
MRP5, was recorded and not only that of MRP1. Also, the
contribution of other, non-ABC transporters such as RLIP76
[22] and aminophospholipid flippase [23], to ATPase activity
measured in erythrocyte membrane could not be excluded.
Stimulation of ATPase activity of both MRP1 and P-
glycoprotein by their substrates is well characterized [24,25].
Phenothiazines have been previously demonstrated to stimulate
ATPase activity of P-gp [26]. The stimulating effect exerted by
phenothiazine maleates on ATPase activity in erythrocyte
membranes may suggest that PhMs bind to MRP proteins
and may be substrates of these transporters.
Contrary to ATPase activity studies, reports on stimulation
of ABC-proteins transport activity are scarce in literature
because the majority of projects concentrate on the search of
the new inhibitors of MDR transporters. Bobrowska-Hager-
stand et al. [20] observed that cationic detergents stimulated
BCPCF efflux from human erythrocytes, whereas anionic
detergents were inhibitors of MRP1 transport activity. We were
able to repeat these observations in our system using Triton X-
100 and SDS as exemplary detergents from both classes. The
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amphiphiles and their impact on BCPCF efflux might reflect
direct charge interaction between polyanionic BCPCF substrate
and detergents. Such an interaction could hinder or facilitate
BCPCF transport by MRP1 depending on modulator’s charac-
ter. Nguyen et al. [27] have shown that flavonoids apigenin,
fisetin, galangin, luteolin, myricetin and rhoifolin were able to
decrease daunomycin accumulation in MRP1-overexpressing
cancer cell line. However, only two compounds from this
group (fisetin and myricetin) were able to decrease accumu-
lation of vinblastine, too. It seemed therefore likely that the
stimulatory effect of a given compound on MRP1 transport
activity could be dependent on the substrate used.
Stimulation of P-glycoprotein transport activity was also
reported (reviewed in [28]). Flavonoids quercetin, kaempferol
and galangin upregulated activity of P-gp that resulted in
markedly decreased accumulation and increased efflux of
adriamycin in multidrug resistant cancer cells [29]. The
stimulatory effect of flavonoids was completely blocked by
known P-gp inhibitors such as verapamil, vinblastine and
quinidine. Sharom et al. [30] demonstrated that some linear
hydrophobic peptides (NAc-Leun-Tyr-amide) and colchicine
mutually stimulated the transport of each other by P-glycopro-
tein in membrane vesicles and reconstituted proteoliposomes.
Also, rhodamine and Hoechst 33342 were reported to stimulate
the P-gp-mediated transport of each other reciprocally [31].
Such an observation led the authors to propose the functional
model of P-glycoprotein containing at least two positively
cooperative sites (R- and H-site) for drug binding and transport.
According to this model, P-gp substrates like rhodamine 123
and anthracyclines bound to R-site, whereas Hoechst 33342,
flavonoid quercetin and colchicine bound to H-site. The results
reported by Kondratov et al. [32] could also be explained
basing on the above model. The authors observed that the
series of small aromatic molecules stimulated efflux of
rhodamine 123, adriamycin and daunorubicin by P-gp, and
inhibited efflux of taxol and Hoechst 33342. Verapamil
blocked the stimulatory effect of these molecules completely.
The above literature reports point very clearly to the existence
of two or more allosteric binding sites on P-glycoprotein. This
is probably why the stimulatory effect of a given class of
modulators is usually observed only for a given substrate (or
class of substrates) and inhibition of transport of other
substrates is recorded.
The presence of multiple binding sites on MRP1 has also
been suggested basing on the experiments on interaction of
photoreactive-iodinated analogue of rhodamine 123 with this
transporter [33]. The situation in case of MRP1 is additionally
complicated by glutathione (GSH) that, besides substrate and
inhibitor, constitutes the third player in modulation of MRP1
transport activity. MRP1 translocates glutathione and glucur-
onate conjugates of many xenobiotics [2], whereas free forms
of anticancer drugs are postulated to be co-transported with
GSH [34]. Glutathione also influences the modulatory action of
many MRP1 inhibitors and transport of substrates. Verapamil
was reported to inhibit MRP1 transport activity only in GSH
presence [35]. Lowering intracellular levels of glutathioneresulted in decreased efflux of calcein from MRP1-expressing
cancer cells but had no effect on BCECF transport [36]. These
observations prompted Evers et al. [37] to propose a working
model of MRP-family transporters. According to this model,
two binding sites on the protein exist (G- and D-site) that act in
positively cooperative manner. The sites can be occupied either
by GSH or by the drug.
Such a model could explain also the stimulation of MRP1
transport activity observed in the present work. We propose
phenothiazine maleates to interact directly with MRP1 at the
site other than occupied by BCPCF and to stimulate BCPCF
transport. However, as PhMs were observed to stimulate
ATPase activity in erythrocyte membrane, it is also possible
that these compounds interact with ATP-binding site of MRP1,
stimulate ATP hydrolysis and in this way stimulate the
transport of fluorescent substrate across the erythrocyte
membrane. It remains also to be solved, whether phenothiazine
derivatives themselves can be transported by MRP1. Since, at
least in case of P-gp, modulating agents usually are able to
stimulate transport of some substrates only while to inhibit the
transport of others, it would be interesting to study the
influence of PhMs on transport of other MRP1 substrates.
Rychlik et al. [4] have studied in details transport of different
fluorescent anions across the human erythrocyte membrane.
The authors clearly demonstrated that among fluorescein,
calcein, carboxyfluorescein and BCECF, only the transport of
the last one could be attributed to MRP1. Therefore, from the
above fluorescent substrates only BCECF seems to be rational
choice to study MRP1 activity in human erythrocytes. To fully
elucidate the mechanism of PhMs-induced MRP1 stimulation
further studies are required employing MRP1-expressing cell
lines. Also studying the influence of phenothiazine derivatives
on glutathione transport could provide additional information.
In summary, our results demonstrate that phenothiazine
maleates, compounds known as P-glycoprotein inhibitors,
stimulate BCPCF efflux from human erythrocytes, BCECF
uptake into inside-out vesicles, and Mg2+-dependent ATPase
activity in erythrocyte membrane. The stimulation of MRP1
transport activity is probably caused by PhMs interaction with
this transporter at the site different from the substrate binding
site.
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